Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Adaptimmune Therapeutics PLC – ADR (ADAP) A Good Stock To Buy?

Page 1 of 2

Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed over the past few years. However, hedge funds are generally partially hedged and aim at delivering attractive risk-adjusted returns rather than following the ups and downs of equity markets hoping that they will outperform the broader market. Our research shows that hedge funds do have great stock picking skills, so let’s take a glance at the smart money sentiment towards Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP).

Adaptimmune Therapeutics’ stock has lost 39% since the beginning of the year and it was in 12 hedge funds’ portfolios at the end of September. However, ADAP investors should be aware of a decrease in hedge fund interest recently. There were 16 hedge funds in our database with ADAP positions at the end of the previous quarter. At the end of this article we will also compare ADAP to other stocks, including SL Industries, Inc. (NYSEMKT:SLI), Violin Memory Inc (NYSE:VMEM), and Collectors Universe, Inc. (NASDAQ:CLCT) to get a better sense of its popularity.

According to most market participants, hedge funds are seen as worthless, outdated financial vehicles of years past. While there are more than 8000 funds in operation at the moment, Our experts look at the bigwigs of this club, about 700 funds. These money managers oversee most of all hedge funds’ total capital, and by tracking their finest equity investments, Insider Monkey has revealed several investment strategies that have historically outpaced the broader indices. Insider Monkey’s small-cap hedge fund strategy outstripped the S&P 500 index by 12 percentage points per annum for a decade in their back tests.

Now, we’re going to take a gander at the new action surrounding Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP).

What have hedge funds been doing with Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP)?

At the end of the third quarter, a total of 12 of the hedge funds tracked by Insider Monkey held long positions in this stock, a decline of 25% from the previous quarter. With the smart money’s positions undergoing their usual ebb and flow, there exists a select group of notable hedge fund managers who were boosting their stakes substantially (or already accumulated large positions).

When looking at the institutional investors followed by Insider Monkey, Christopher James’ Partner Fund Management has the largest position in Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP), worth close to $12 million, amounting to 0.3% of its total 13F portfolio. Sitting at the No. 2 spot is Rock Springs Capital Management, managed by Kris Jenner, Gordon Bussard, Graham McPhail, which holds a $9.1 million position; the fund has 0.7% of its 13F portfolio invested in the stock. Remaining peers with similar optimism consist of Ken Griffin’s Citadel Investment Group, Phill Gross and Robert Atchinson’s Adage Capital Management, and Daniel Gold’s QVT Financial.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!